Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Johnson & Johnson (JNJ)
NYSE:JNJ
Holding JNJ?
Track your performance easily
JNJ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$140.68 - $168.85
Previous CloseN/A
Volume3.80M
Average Volume (3M)8.48M
Market Cap
$348.50B
Enterprise Value$407.32B
Total Cash (Recent Filing)$41.91B
Total Debt (Recent Filing)$22.44B
Price to Earnings (P/E)24.0
Beta0.26
Next Earnings
Jan 22, 2025EPS Estimate
2.03Next Dividend Ex-Date
Feb 18, 2025Dividend Yield3.39%
Share Statistics
EPS (TTM)6.05
Shares Outstanding2,407,623,000
10 Day Avg. Volume8,362,234
30 Day Avg. Volume8,483,849
Standard Deviation0.05
R-Squared0.29
Alpha-0.00247
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.98
Price to Cash Flow (P/CF)10.90
P/FCF Ratio12.30
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue5.10
Enterprise Value/Gross Profit6.95
Enterprise Value/Ebitda16.60
Forecast
1Y Price Target
$169.00Price Target Upside14.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Johnson & Johnson News
Bulls Say, Bears Say
Bulls Say
Product ExpansionCaplyta's potential expansion into treating major depressive disorders could significantly increase its addressable market, boosting its sales potential.
Sales Growth PotentialThe acquisition of ITCI could be accretive to sales growth in the first full year and to earnings in the second full year.
Strategic AcquisitionThe acquisition of Intra-Cellular Therapies is a strategic fit for Johnson & Johnson, enhancing its existing presence in the central nervous system and neuro sectors.
Bears Say
Acquisitions And Financial ImpactThere is potential for the acquisition to impact JNJ's AAA credit rating due to increased debt.
Financial Guidance And EarningsJNJ lowered its full-year adjusted operational sales growth target for MedTech to 'closer to 5%' from 6% previously due to softness in the Asia-Pacific region, particularly in China.
Product And Market PerformanceMedTech sales growth was softer than expected, missing both consensus and internal estimates.
---
Ownership Overview
0.04% Insiders
18.42% Mutual Funds
0.66% Other Institutional Investors
60.44% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
JNJ FAQ
What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest stock price was $140.68 and its highest was $168.85 in the past 12 months.
What is Johnson & Johnson’s market cap?
Johnson & Johnson’s market cap is $348.50B.
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s upcoming earnings report date is Jan 22, 2025 which is in 4 days.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Oct 15, 2024. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.207 by $0.213.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson pays a Quarterly dividend of $4.91 which represents an annual dividend yield of 3.39%. See more information on Johnson & Johnson dividends here
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is 2.03.
How many shares outstanding does Johnson & Johnson have?
Johnson & Johnson has 2,407,623,000 shares outstanding.
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of $2.42 in its last earnings report, beating expectations of $2.207. Following the earnings report the stock price went up 1.547%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Among the largest hedge funds holding Johnson & Johnson’s share is Fisher Asset Management LLC. It holds Johnson & Johnson’s shares valued at 1B.
---
Johnson & Johnson Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$169.00 (14.37% Upside)
$169.00 (14.37% Upside)
Blogger Sentiment
Bullish
JNJ Sentiment 92%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 189.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $147.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Very Bullish
Bullish news 86%
Bearish news 14%
Bearish news 14%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.02%
12-Months-Change
Fundamentals
Return on Equity
20.93%
Trailing 12-Months
Asset Growth
7.36%
Trailing 12-Months
Company Description
Johnson & Johnson
Johnson & Johnson provides healthcare products across three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
---
JNJ Company Deck
---
JNJ Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
Johnson & Johnson reported robust sales growth and pipeline advancements in Q3 2024, particularly in Innovative Medicine and MedTech segments. However, earnings were impacted by legal settlement costs and challenges in the Asia Pacific region. Despite these challenges, the company remains confident in its growth trajectory.Read More>---
JNJ Sales Breakdown
64.30% Innovative Medicine
35.70% MedTech
---
JNJ Stock 12 Month Forecast
Average Price Target
$169.00
▲(14.37% Upside)
Technical Analysis
Best Analysts Covering JNJ
1 Year
1 Year Success Rate
22/23 ratings generated profit
1 Year Average Return
+9.17%
reiterated a buy rating 8 months ago
Copying Danielle Antalffy's trades and holding each position for 1 Year would result in 95.65% of your transactions generating a profit, with an average return of +9.17% per trade.
---